Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Muppidi, S, Utsugisawa, K, Benatar, M, Murai, H, Barohn, RJ, Illa, I, Jacob, S, Vissing, J, Burns, TM, Kissel, JT, Nowak, RJ, Andersen, H, Casasnovas, C, de Bleecker, JL, Vu, TH, Mantegazza, R, O'Brien, FL, Wang, JJ, Fujita, KP, Howard, JF & REGAIN Study Group 2019, 'Long-term safety and efficacy of eculizumab in generalized myasthenia gravis', Muscle & Nerve, vol. 60, no. 1, pp. 14-24. https://doi.org/10.1002/mus.26447

APA

Muppidi, S., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., Jacob, S., Vissing, J., Burns, T. M., Kissel, J. T., Nowak, R. J., Andersen, H., Casasnovas, C., de Bleecker, J. L., Vu, T. H., Mantegazza, R., O'Brien, F. L., Wang, J. J., Fujita, K. P., ... REGAIN Study Group (2019). Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle & Nerve, 60(1), 14-24. https://doi.org/10.1002/mus.26447

CBE

Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF, REGAIN Study Group. 2019. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle & Nerve. 60(1):14-24. https://doi.org/10.1002/mus.26447

MLA

Vancouver

Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle & Nerve. 2019 Jul 1;60(1):14-24. https://doi.org/10.1002/mus.26447

Author

Muppidi, Srikanth ; Utsugisawa, Kimiaki ; Benatar, Michael ; Murai, Hiroyuki ; Barohn, Richard J ; Illa, Isabel ; Jacob, Saiju ; Vissing, John ; Burns, Ted M ; Kissel, John T ; Nowak, Richard J ; Andersen, Henning ; Casasnovas, Carlos ; de Bleecker, Jan L ; Vu, Tuan H ; Mantegazza, Renato ; O'Brien, Fanny L ; Wang, Jing Jing ; Fujita, Kenji P ; Howard, James F ; REGAIN Study Group. / Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. In: Muscle & Nerve. 2019 ; Vol. 60, No. 1. pp. 14-24.

Bibtex

@article{694e4932917c426a89c459aac1e83803,
title = "Long-term safety and efficacy of eculizumab in generalized myasthenia gravis",
abstract = "Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. Methods: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients. Results: The safety profile of eculizumab was consistent with REGAIN; no cases of meningococcal infection were reported during the interim analysis period. Myasthenia gravis exacerbation rate was reduced by 75% from the year before REGAIN (P < 0.0001). Improvements with eculizumab in activities of daily living, muscle strength, functional ability, and quality of life in REGAIN were maintained through 3 years; 56% of patients achieved minimal manifestations or pharmacological remission. Patients who had received placebo during REGAIN experienced rapid and sustained improvements during open-label eculizumab (P < 0.0001). Discussion: These findings provide evidence for the long-term safety and sustained efficacy of eculizumab for refractory gMG. Muscle Nerve 2019.",
keywords = "MG-ADL, MG-QOL15, MGC, QMG, eculizumab, myasthenia gravis",
author = "Srikanth Muppidi and Kimiaki Utsugisawa and Michael Benatar and Hiroyuki Murai and Barohn, {Richard J} and Isabel Illa and Saiju Jacob and John Vissing and Burns, {Ted M} and Kissel, {John T} and Nowak, {Richard J} and Henning Andersen and Carlos Casasnovas and {de Bleecker}, {Jan L} and Vu, {Tuan H} and Renato Mantegazza and O'Brien, {Fanny L} and Wang, {Jing Jing} and Fujita, {Kenji P} and Howard, {James F} and {REGAIN Study Group}",
note = "{\textcopyright} 2019 The Authors. Muscle & Nerve published by Wiley Periodicals, Inc.",
year = "2019",
month = jul,
day = "1",
doi = "10.1002/mus.26447",
language = "English",
volume = "60",
pages = "14--24",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John/Wiley & Sons, Inc. John/Wiley & Sons Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Long-term safety and efficacy of eculizumab in generalized myasthenia gravis

AU - Muppidi, Srikanth

AU - Utsugisawa, Kimiaki

AU - Benatar, Michael

AU - Murai, Hiroyuki

AU - Barohn, Richard J

AU - Illa, Isabel

AU - Jacob, Saiju

AU - Vissing, John

AU - Burns, Ted M

AU - Kissel, John T

AU - Nowak, Richard J

AU - Andersen, Henning

AU - Casasnovas, Carlos

AU - de Bleecker, Jan L

AU - Vu, Tuan H

AU - Mantegazza, Renato

AU - O'Brien, Fanny L

AU - Wang, Jing Jing

AU - Fujita, Kenji P

AU - Howard, James F

AU - REGAIN Study Group

N1 - © 2019 The Authors. Muscle & Nerve published by Wiley Periodicals, Inc.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. Methods: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients. Results: The safety profile of eculizumab was consistent with REGAIN; no cases of meningococcal infection were reported during the interim analysis period. Myasthenia gravis exacerbation rate was reduced by 75% from the year before REGAIN (P < 0.0001). Improvements with eculizumab in activities of daily living, muscle strength, functional ability, and quality of life in REGAIN were maintained through 3 years; 56% of patients achieved minimal manifestations or pharmacological remission. Patients who had received placebo during REGAIN experienced rapid and sustained improvements during open-label eculizumab (P < 0.0001). Discussion: These findings provide evidence for the long-term safety and sustained efficacy of eculizumab for refractory gMG. Muscle Nerve 2019.

AB - Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. Methods: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients. Results: The safety profile of eculizumab was consistent with REGAIN; no cases of meningococcal infection were reported during the interim analysis period. Myasthenia gravis exacerbation rate was reduced by 75% from the year before REGAIN (P < 0.0001). Improvements with eculizumab in activities of daily living, muscle strength, functional ability, and quality of life in REGAIN were maintained through 3 years; 56% of patients achieved minimal manifestations or pharmacological remission. Patients who had received placebo during REGAIN experienced rapid and sustained improvements during open-label eculizumab (P < 0.0001). Discussion: These findings provide evidence for the long-term safety and sustained efficacy of eculizumab for refractory gMG. Muscle Nerve 2019.

KW - MG-ADL

KW - MG-QOL15

KW - MGC

KW - QMG

KW - eculizumab

KW - myasthenia gravis

UR - http://www.scopus.com/inward/record.url?scp=85062729927&partnerID=8YFLogxK

U2 - 10.1002/mus.26447

DO - 10.1002/mus.26447

M3 - Journal article

C2 - 30767274

VL - 60

SP - 14

EP - 24

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 1

ER -

ID: 58110164